Three-dimensional cartilage formation by bone marrow-derived cells seeded in polylactide/alginate amalgam

Current approaches to cartilage repair face limitations in scaffold design and cell source selection. Prior research has shown that bone marrow-derived cells can undergo chondrogenesis under specific in vitro conditions. However, the effectiveness of these cells within composite scaffolds remains unclear. Established knowledge includes the role of TGF-beta 1 in promoting chondrogenic differentiation. This gap motivated the investigation of how scaffold composition influences cell behavior. No prior work had resolved the optimal combination of biodegradable polymers and cell retention strategies. The study aimed to address this uncertainty by testing a PLA/alginate construct. This uncertainty drove the evaluation of both mechanical and biochemical factors in cartilage formation. The research sought to clarify how scaffold design impacts cellular outcomes.

The study aimed to assess the suitability of a three-dimensional PLA/alginate scaffold for cartilage tissue engineering. Bone marrow-derived cells were selected for their chondrogenic potential. The primary objective was to determine if these cells could form cartilage within the composite scaffold. The study also sought to compare different TGF-beta 1 treatment regimens. Researchers hypothesized that scaffold composition would influence cell behavior. They proposed that the PLA/alginate amalgam would support chondrogenesis. This hypothesis was based on the known roles of PLA and alginate in tissue engineering. The study aimed to provide evidence for scaffold design optimization.

The study utilized human bone marrow-derived cells suspended in alginate or medium. These cells were loaded into porous PLA blocks to create composite constructs. Alginate was incorporated to enhance cell retention within the scaffold. The PLA component provided structural support and stability. Constructs were treated with varying concentrations of TGF-beta 1. Treatments included continuous low-dose and short-term high-dose regimens. Cultures were maintained for up to 21 days with weekly assessments. Histological and immunohistochemical analyses evaluated chondrogenic differentiation.

Histological analysis revealed cartilage-like structures in TGF-beta 1-treated constructs. Alcian blue staining showed proteoglycan accumulation in the extracellular matrix. Collagen type II and cartilage link protein were co-localized in treated samples. Gene expression analysis confirmed upregulation of chondrogenic markers. Collagen types II and IX, along with aggrecan, were detected in treated cultures. Scanning electron microscopy showed rounded cell morphology in the amalgam. Both treatment regimens induced chondrogenic differentiation. The 50 ng/mL initial treatment was as effective as continuous 10 ng/mL exposure.

The study demonstrated that the PLA/alginate amalgam supports chondrogenesis of bone marrow-derived cells. TGF-beta 1 treatment, either continuous or short-term, induced cartilage formation. Histological and gene expression data confirmed the development of a cartilaginous phenotype. Scaffold composition influenced cell behavior and matrix production. The amalgam provided both mechanical stability and cell retention. The findings suggest that early TGF-beta 1 exposure is sufficient for differentiation. This outcome aligns with the authors' hypothesis about scaffold design. The results support further investigation into the clinical potential of this composite scaffold.